PRQR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders...

Stats
Dzisiejszy wolumen	228 504
Średni wolumen	204 070
Kapitalizacja rynkowa	161.63M
EPS	€0 ( 2024-04-03 )
Następna data zysków	( €-0.120 ) 2024-05-21
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.41
ATR14	€0.0150 (0.75%)

Wolumen Korelacja

Długi: 0.14 (neutral)

Krótki: 0.74 (moderate)

Signal:(53.792) Neutral

ProQR Therapeutics NV Korelacja

10 Najbardziej pozytywne korelacje
ECHO	0.961
SIOX	0.958
MLVF	0.954
IIN	0.95
CDZI	0.949
EXAS	0.942
BTWN	0.94
EXFO	0.934
GDNR	0.933
BKCH	0.932

10 Najbardziej negatywne korelacje
SNPX	-0.971
UTME	-0.963
ISPO	-0.956
PDBC	-0.95
LARK	-0.944
KTTA	-0.943
RIVN	-0.937
OP	-0.936
HMNF	-0.934
PIII	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProQR Therapeutics NV Korelacja - Waluta/Towar

0.03
( neutral )

-0.02
( neutral )

0.77
( moderate )

0.20
( neutral )

-0.07
( neutral )

ProQR Therapeutics NV Finanse

Annual	2023
Przychody:	€6.38M
Zysk brutto:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2023
Przychody:	€6.38M
Zysk brutto:	€6.38M (100.00 %)
EPS:	€-0.340

FY	2022
Przychody:	€4.04M
Zysk brutto:	€1.56M (38.68 %)
EPS:	€-0.910

FY	2021
Przychody:	€1.35M
Zysk brutto:	€0.00 (0.00 %)
EPS:	€-1.231

Financial Reports:

No articles found.

ProQR Therapeutics NV

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.